Huang 2002.
Study characteristics | ||
Methods | Parallel design Aim: efficacy and tolerance of fluoxetine in early post‐stroke depression Analysis: according to treatment group |
|
Participants | Country: China Setting: inpatient Stroke criteria: first ever stroke, with single unilateral lesion, clinical diagnosis with imaging consistent with stroke, both ischaemic and haemorrhagic, recruited 2 weeks after stroke onset Depression criteria: CCMD II‐R depression diagnosis Treatment: 40 people, age and gender not stated Control: 40 people, age and gender not stated Participants in the treatment and control groups were selected from a group of 168 first‐ever acute stroke patients with average age of 62 ± 8.1 years, 76 men |
|
Interventions | Treatment: fluoxetine 20 mg daily Control: placebo Duration of treatment: 4 weeks Duration of follow‐up (treatment end to study end): 0 |
|
Outcomes | HAMD CSS Did not report death Unclear how AEs were reported: no obvious AEs were found, but they did not specifically report seizures |
|
Funding source | Source of funding not stated | |
Notes | − | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Method not stated |
Allocation concealment (selection bias) | Unclear risk | Method not stated |
Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | Placebo used, but unclear if identical |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Not described |
Incomplete outcome data (attrition bias) All outcomes | Low risk | No dropouts, analysed according to treatment group |
Selective reporting (reporting bias) | Unclear risk | No protocol |
Other bias | Unclear risk | No description of the differences between treatment and control group in baseline characteristics |